NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|939619640|ref|NP_609916|]
View 

uncharacterized protein Dmel_CG10602, isoform F [Drosophila melanogaster]

Protein Classification

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
79-681 0e+00

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


:

Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 1010.46  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640   79 DPSSYSQPDLITTEHSALNWKIDFAATKIQGSVLHRFKVLTANLDKILLDVRDINVTNATLLAggseLPINFFISDAVDD 158
Cdd:TIGR02411   1 DPSSLSNYKDFRTSHTDLNLSVDFTKRKLSGSVTFTLKSLTDNLNKLVLDTSYLDIQKVTING----LPADFAIGERKEP 76
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  159 IGQKLTLELPSGTAKG-SLNVRIDYETSSSASGLQWLNPTQTLGKEHPYMFSQCQAIHARSVIPCQDTPAVKFTYDATVE 237
Cdd:TIGR02411  77 LGSPLTISLPIATSKNdEFVLNISFSTTPKCTALQWLNPEQTSGKKHPYLFSQCQAIHARSLFPCQDTPSVKSTYTAEVE 156
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  238 HPseLTALMSALID---KKEPGKTLFKQEVPIPAYLVAIAIGKLVSRPLGENSSVWAEEAIVDACAEEFS-ETATMLKTA 313
Cdd:TIGR02411 157 SP--LPVLMSGIRDgetSNDPGKYLFKQKVPIPAYLIAIASGDLASAPIGPRSTVYSEPEQLEKCQYEFEnDTEKFIKTA 234
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  314 TELCGPYVWKQYDLLVMPPSFPFGGMENPCLTFVTPTLLAGDKSLADVVAHEIAHSWTGNLVTNKNFEHFWLNEGFTVFV 393
Cdd:TIGR02411 235 EDLIFPYEWGQYDLLVLPPSFPYGGMENPNLTFATPTLIAGDRSNVDVIAHELAHSWSGNLVTNCSWEHFWLNEGWTVYL 314
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  394 ESKIVGRMQGAKELDFKMLSNLTDLQECIRTqLNKTPELTKLVVDLSNCGPDDAFSSVPYIKGSTFLRYLEDLFGGPTVF 473
Cdd:TIGR02411 315 ERRIIGRLYGEKTRHFSALIGWGDLQESVKT-LGETPEFTKLVVDLKDNDPDDAFSSVPYEKGFNFLFYLEQLLGGPAEF 393
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  474 EPFLRDYLKKYAYKSIETKDFQSALYDYFIDTDKKDKLSAVDWDLWLKSEGMPPVIPNFDESLANVTKELASLWSSKSVA 553
Cdd:TIGR02411 394 DPFLRHYFKKFAYKSLDTYQFKDALYEYFKDKKKVDKLDAVDWETWLYSPGMPPVKPNFDTTLADECYALADRWVDAAKA 473
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  554 -ELAD-SAEIKTTISIHQLIDFLGKLIESKDIVDLNEGKINLLESTYNLKSSKNAEVRFRLNRLIIRARLIKRLDEILEF 631
Cdd:TIGR02411 474 dDLSSfNAKDIKDFSSHQLVLFLETLTERGGDWALPEGHIKRLGDIYNFAASKNAEVRFRWFRLAIQAKLEDEYPLLADW 553
                         570       580       590       600       610
                  ....*....|....*....|....*....|....*....|....*....|
gi 939619640  632 ANSNFRMKFCRPIYRDLAGWpEAKPAAIRNFVNVKDQMMAVCSHTIEKDL 681
Cdd:TIGR02411 554 LGTVGRMKFVRPGYRLLNAF-VDRDLAIRTFEKFKDSYHPICAMLVKKDL 602
Ribosomal_L13 super family cl46662
Ribosomal protein L13;
15-50 6.95e-08

Ribosomal protein L13;


The actual alignment was detected with superfamily member pfam00572:

Pssm-ID: 459856  Cd Length: 119  Bit Score: 51.42  E-value: 6.95e-08
                          10        20        30
                  ....*....|....*....|....*....|....*.
gi 939619640   15 RTWHIYDCTWQNPFESAKLVKTHLLGLQKPIYHPMI 50
Cdd:pfam00572   1 RKWHVVDAKGQILGRLASKIAKLLRGKHKPIYHPHV 36
 
Name Accession Description Interval E-value
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
79-681 0e+00

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 1010.46  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640   79 DPSSYSQPDLITTEHSALNWKIDFAATKIQGSVLHRFKVLTANLDKILLDVRDINVTNATLLAggseLPINFFISDAVDD 158
Cdd:TIGR02411   1 DPSSLSNYKDFRTSHTDLNLSVDFTKRKLSGSVTFTLKSLTDNLNKLVLDTSYLDIQKVTING----LPADFAIGERKEP 76
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  159 IGQKLTLELPSGTAKG-SLNVRIDYETSSSASGLQWLNPTQTLGKEHPYMFSQCQAIHARSVIPCQDTPAVKFTYDATVE 237
Cdd:TIGR02411  77 LGSPLTISLPIATSKNdEFVLNISFSTTPKCTALQWLNPEQTSGKKHPYLFSQCQAIHARSLFPCQDTPSVKSTYTAEVE 156
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  238 HPseLTALMSALID---KKEPGKTLFKQEVPIPAYLVAIAIGKLVSRPLGENSSVWAEEAIVDACAEEFS-ETATMLKTA 313
Cdd:TIGR02411 157 SP--LPVLMSGIRDgetSNDPGKYLFKQKVPIPAYLIAIASGDLASAPIGPRSTVYSEPEQLEKCQYEFEnDTEKFIKTA 234
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  314 TELCGPYVWKQYDLLVMPPSFPFGGMENPCLTFVTPTLLAGDKSLADVVAHEIAHSWTGNLVTNKNFEHFWLNEGFTVFV 393
Cdd:TIGR02411 235 EDLIFPYEWGQYDLLVLPPSFPYGGMENPNLTFATPTLIAGDRSNVDVIAHELAHSWSGNLVTNCSWEHFWLNEGWTVYL 314
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  394 ESKIVGRMQGAKELDFKMLSNLTDLQECIRTqLNKTPELTKLVVDLSNCGPDDAFSSVPYIKGSTFLRYLEDLFGGPTVF 473
Cdd:TIGR02411 315 ERRIIGRLYGEKTRHFSALIGWGDLQESVKT-LGETPEFTKLVVDLKDNDPDDAFSSVPYEKGFNFLFYLEQLLGGPAEF 393
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  474 EPFLRDYLKKYAYKSIETKDFQSALYDYFIDTDKKDKLSAVDWDLWLKSEGMPPVIPNFDESLANVTKELASLWSSKSVA 553
Cdd:TIGR02411 394 DPFLRHYFKKFAYKSLDTYQFKDALYEYFKDKKKVDKLDAVDWETWLYSPGMPPVKPNFDTTLADECYALADRWVDAAKA 473
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  554 -ELAD-SAEIKTTISIHQLIDFLGKLIESKDIVDLNEGKINLLESTYNLKSSKNAEVRFRLNRLIIRARLIKRLDEILEF 631
Cdd:TIGR02411 474 dDLSSfNAKDIKDFSSHQLVLFLETLTERGGDWALPEGHIKRLGDIYNFAASKNAEVRFRWFRLAIQAKLEDEYPLLADW 553
                         570       580       590       600       610
                  ....*....|....*....|....*....|....*....|....*....|
gi 939619640  632 ANSNFRMKFCRPIYRDLAGWpEAKPAAIRNFVNVKDQMMAVCSHTIEKDL 681
Cdd:TIGR02411 554 LGTVGRMKFVRPGYRLLNAF-VDRDLAIRTFEKFKDSYHPICAMLVKKDL 602
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
79-520 0e+00

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 693.82  E-value: 0e+00
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  79 DPSSYSQPDLITTEHSALNWKIDFAATKIQGSVLHRFKVLTANLDKILLDVRDINVTNATLlagGSELPINFFISDAVDD 158
Cdd:cd09599    1 DPSSFSNYDEVRTTHLDLDLTVDFDKKTISGSATLTLEVLQDGADELVLDTRDLDISSVTV---NGGKELKFELGPRDPV 77
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 159 IGQKLTLELPSGTAKGS-LNVRIDYETSSSASGLQWLNPTQTLGKEHPYMFSQCQAIHARSVIPCQDTPAVKFTYDATVE 237
Cdd:cd09599   78 LGSALTITLPSPLAKGDtFKVKIEYSTTPQATALQWLTPEQTAGKKHPYLFTQCQAIHARSLFPCQDTPSVKSTYSATVT 157
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 238 HPSELTALMSALIDKKEP----GKTLFKQEVPIPAYLVAIAIGKLVSRPLGENSSVWAEEAIVDACAEEFSETATMLKTA 313
Cdd:cd09599  158 VPKGLTALMSALRTGEKEeagtGTYTFEQPVPIPSYLIAIAVGDLESREIGPRSGVWAEPSVVDAAAEEFADTEKFLKAA 237
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 314 TELCGPYVWKQYDLLVMPPSFPFGGMENPCLTFVTPTLLAGDKSLADVVAHEIAHSWTGNLVTNKNFEHFWLNEGFTVFV 393
Cdd:cd09599  238 EKLYGPYVWGRYDLLVLPPSFPYGGMENPCLTFATPTLIAGDRSLVDVIAHEIAHSWSGNLVTNANWEHFWLNEGFTVYL 317
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 394 ESKIVGRMQGAKELDFKMLSNLTDLQECIRTqLNKTPELTKLVVDLSNCGPDDAFSSVPYIKGSTFLRYLEDLfGGPTVF 473
Cdd:cd09599  318 ERRILERLYGEEYRQFEAILGWKDLQESIKE-FGEDPPYTLLVPDLKGVDPDDAFSSVPYEKGFQFLYYLEQL-GGREVF 395
                        410       420       430       440
                 ....*....|....*....|....*....|....*....|....*..
gi 939619640 474 EPFLRDYLKKYAYKSIETKDFQSALYDYFIDtDKKDKLSAVDWDLWL 520
Cdd:cd09599  396 DPFLRAYFKKFAFQSIDTEDFKDFLLEYFAE-DKPEILDKIDWDAWL 441
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
72-528 5.14e-97

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 311.19  E-value: 5.14e-97
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  72 MGRLGVVDPssYsQPDLITTEHSALNWKIDFAATKIQGSVLHRFKVLTANLDKILLDVRDINVTNATLlaGGSELPinfF 151
Cdd:COG0308    1 MKRLTRLEA--Y-RPPGYDVTHYDLDLDLDPATTRLSGTATITFTATEAPLDSLVLDLKGLEVTSVTV--DGKPLD---F 72
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 152 ISDavddiGQKLTLELPSGTAKGSLN-VRIDYET--SSSASGLQWLNPTqtlGKEHPYMFSQCQAIHARSVIPCQDTPAV 228
Cdd:COG0308   73 TRD-----GERLTITLPKPLAPGETFtLEIEYSGkpSNGGEGLYRSGDP---PDGPPYLYTQCEPEGARRWFPCFDHPDD 144
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 229 KFTYDATVEHPSELTALMSA-LIDKKEPGKTL----FKQEVPIPAYLVAIAIGKLVSRPLGENSSV----WAEEAIVDAC 299
Cdd:COG0308  145 KATFTLTVTVPAGWVAVSNGnLVSETELGDGRttwhWADTQPIPTYLFALAAGDYAVVEDTFASGVplrvYVRPGLADKA 224
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 300 AEEFSETATMLKTATELCG-PYVWKQYDLLVMPpSFPFGGMENPCLTFVTPTLLAGD-------KSLADVVAHEIAHSWT 371
Cdd:COG0308  225 KEAFESTKRMLDFFEELFGvPYPFDKYDQVAVP-DFNFGAMENQGLVTFGEKVLADEtatdadyERRESVIAHELAHQWF 303
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 372 GNLVTNKNFEHFWLNEGFTVFVESKIVGRMQGAKELDFKMLSNLTDLQECIRTQLNKTPeltklVVDLSNCGPDDAFSSV 451
Cdd:COG0308  304 GNLVTCADWDDLWLNEGFATYMEQLFSEDLYGKDAADRIFVGALRSYAFAEDAGPNAHP-----IRPDDYPEIENFFDGI 378
                        410       420       430       440       450       460       470
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 939619640 452 PYIKGSTFLRYLEDLFgGPTVFEPFLRDYLKKYAYKSIETKDFQSALYDYfidTDKkdKLSAVdWDLWLKSEGMPPV 528
Cdd:COG0308  379 VYEKGALVLHMLRTLL-GDEAFRAGLRLYFARHAGGNATTEDFLAALEEA---SGR--DLSAF-FDQWLYQAGLPTL 448
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
319-519 7.28e-52

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 178.64  E-value: 7.28e-52
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  319 PYVWKQYDLLVMPpSFPFGGMENPCLTFVTPTLLAGD---------KSLADVVAHEIAHSWTGNLVTNKNFEHFWLNEGF 389
Cdd:pfam01433  20 PYPLPKYDLVALP-DFSAGAMENWGLITYRETLLLYDpgnsstsdkQRVASVIAHELAHQWFGNLVTMKWWDDLWLNEGF 98
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  390 TVFVESKIVGRMQGakelDFKMLSNLTDLQECIRTQLNKTPELTKLVVDLSNCG-PDDAFSSVPYIKGSTFLRYLEDLFg 468
Cdd:pfam01433  99 ATYMEYLGTDALFP----EWNIWEQFLLDEVQNAMARDALDSSHPITQNVNDPSeIDDIFDAIPYEKGASVLRMLETLL- 173
                         170       180       190       200       210
                  ....*....|....*....|....*....|....*....|....*....|.
gi 939619640  469 GPTVFEPFLRDYLKKYAYKSIETKDFQSALYDYfidTDKKDkLSAVdWDLW 519
Cdd:pfam01433 174 GEEVFQKGLRSYLKKFQYGNATTEDLWDALSEA---SGPLD-VDSF-MDTW 219
Ribosomal_L13 pfam00572
Ribosomal protein L13;
15-50 6.95e-08

Ribosomal protein L13;


Pssm-ID: 459856  Cd Length: 119  Bit Score: 51.42  E-value: 6.95e-08
                          10        20        30
                  ....*....|....*....|....*....|....*.
gi 939619640   15 RTWHIYDCTWQNPFESAKLVKTHLLGLQKPIYHPMI 50
Cdd:pfam00572   1 RKWHVVDAKGQILGRLASKIAKLLRGKHKPIYHPHV 36
Ribosomal_L13 cd00392
Ribosomal protein L13. Protein L13, a large ribosomal subunit protein, is one of five ...
17-52 1.51e-05

Ribosomal protein L13. Protein L13, a large ribosomal subunit protein, is one of five proteins required for an early folding intermediate of 23S rRNA in the assembly of the large subunit. L13 is situated on the bottom of the large subunit, near the polypeptide exit site. It interacts with proteins L3 and L6, and forms an extensive network of interactions with 23S rRNA. L13 has been identified as a homolog of the human breast basic conserved protein 1 (BBC1), a protein identified through its increased expression in breast cancer. L13 expression is also upregulated in a variety of human gastrointestinal cancers, suggesting it may play a role in the etiology of a variety of human malignancies.


Pssm-ID: 238230  Cd Length: 114  Bit Score: 44.42  E-value: 1.51e-05
                         10        20        30
                 ....*....|....*....|....*....|....*.
gi 939619640  17 WHIYDCTWQNPFESAKLVKTHLLGLQKPIYHPMIST 52
Cdd:cd00392    1 WHVIDAKGQVLGRLASKVAKLLLGKHKPTYTPHVDC 36
pepN PRK14015
aminopeptidase N; Provisional
361-392 9.08e-04

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 42.43  E-value: 9.08e-04
                         10        20        30
                 ....*....|....*....|....*....|....*.
gi 939619640 361 VVAHEIAHSWTGNLVTNKNfehfW----LNEGFTVF 392
Cdd:PRK14015 299 VIAHEYFHNWTGNRVTCRD----WfqlsLKEGLTVF 330
 
Name Accession Description Interval E-value
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
79-681 0e+00

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 1010.46  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640   79 DPSSYSQPDLITTEHSALNWKIDFAATKIQGSVLHRFKVLTANLDKILLDVRDINVTNATLLAggseLPINFFISDAVDD 158
Cdd:TIGR02411   1 DPSSLSNYKDFRTSHTDLNLSVDFTKRKLSGSVTFTLKSLTDNLNKLVLDTSYLDIQKVTING----LPADFAIGERKEP 76
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  159 IGQKLTLELPSGTAKG-SLNVRIDYETSSSASGLQWLNPTQTLGKEHPYMFSQCQAIHARSVIPCQDTPAVKFTYDATVE 237
Cdd:TIGR02411  77 LGSPLTISLPIATSKNdEFVLNISFSTTPKCTALQWLNPEQTSGKKHPYLFSQCQAIHARSLFPCQDTPSVKSTYTAEVE 156
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  238 HPseLTALMSALID---KKEPGKTLFKQEVPIPAYLVAIAIGKLVSRPLGENSSVWAEEAIVDACAEEFS-ETATMLKTA 313
Cdd:TIGR02411 157 SP--LPVLMSGIRDgetSNDPGKYLFKQKVPIPAYLIAIASGDLASAPIGPRSTVYSEPEQLEKCQYEFEnDTEKFIKTA 234
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  314 TELCGPYVWKQYDLLVMPPSFPFGGMENPCLTFVTPTLLAGDKSLADVVAHEIAHSWTGNLVTNKNFEHFWLNEGFTVFV 393
Cdd:TIGR02411 235 EDLIFPYEWGQYDLLVLPPSFPYGGMENPNLTFATPTLIAGDRSNVDVIAHELAHSWSGNLVTNCSWEHFWLNEGWTVYL 314
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  394 ESKIVGRMQGAKELDFKMLSNLTDLQECIRTqLNKTPELTKLVVDLSNCGPDDAFSSVPYIKGSTFLRYLEDLFGGPTVF 473
Cdd:TIGR02411 315 ERRIIGRLYGEKTRHFSALIGWGDLQESVKT-LGETPEFTKLVVDLKDNDPDDAFSSVPYEKGFNFLFYLEQLLGGPAEF 393
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  474 EPFLRDYLKKYAYKSIETKDFQSALYDYFIDTDKKDKLSAVDWDLWLKSEGMPPVIPNFDESLANVTKELASLWSSKSVA 553
Cdd:TIGR02411 394 DPFLRHYFKKFAYKSLDTYQFKDALYEYFKDKKKVDKLDAVDWETWLYSPGMPPVKPNFDTTLADECYALADRWVDAAKA 473
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  554 -ELAD-SAEIKTTISIHQLIDFLGKLIESKDIVDLNEGKINLLESTYNLKSSKNAEVRFRLNRLIIRARLIKRLDEILEF 631
Cdd:TIGR02411 474 dDLSSfNAKDIKDFSSHQLVLFLETLTERGGDWALPEGHIKRLGDIYNFAASKNAEVRFRWFRLAIQAKLEDEYPLLADW 553
                         570       580       590       600       610
                  ....*....|....*....|....*....|....*....|....*....|
gi 939619640  632 ANSNFRMKFCRPIYRDLAGWpEAKPAAIRNFVNVKDQMMAVCSHTIEKDL 681
Cdd:TIGR02411 554 LGTVGRMKFVRPGYRLLNAF-VDRDLAIRTFEKFKDSYHPICAMLVKKDL 602
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
79-520 0e+00

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 693.82  E-value: 0e+00
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  79 DPSSYSQPDLITTEHSALNWKIDFAATKIQGSVLHRFKVLTANLDKILLDVRDINVTNATLlagGSELPINFFISDAVDD 158
Cdd:cd09599    1 DPSSFSNYDEVRTTHLDLDLTVDFDKKTISGSATLTLEVLQDGADELVLDTRDLDISSVTV---NGGKELKFELGPRDPV 77
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 159 IGQKLTLELPSGTAKGS-LNVRIDYETSSSASGLQWLNPTQTLGKEHPYMFSQCQAIHARSVIPCQDTPAVKFTYDATVE 237
Cdd:cd09599   78 LGSALTITLPSPLAKGDtFKVKIEYSTTPQATALQWLTPEQTAGKKHPYLFTQCQAIHARSLFPCQDTPSVKSTYSATVT 157
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 238 HPSELTALMSALIDKKEP----GKTLFKQEVPIPAYLVAIAIGKLVSRPLGENSSVWAEEAIVDACAEEFSETATMLKTA 313
Cdd:cd09599  158 VPKGLTALMSALRTGEKEeagtGTYTFEQPVPIPSYLIAIAVGDLESREIGPRSGVWAEPSVVDAAAEEFADTEKFLKAA 237
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 314 TELCGPYVWKQYDLLVMPPSFPFGGMENPCLTFVTPTLLAGDKSLADVVAHEIAHSWTGNLVTNKNFEHFWLNEGFTVFV 393
Cdd:cd09599  238 EKLYGPYVWGRYDLLVLPPSFPYGGMENPCLTFATPTLIAGDRSLVDVIAHEIAHSWSGNLVTNANWEHFWLNEGFTVYL 317
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 394 ESKIVGRMQGAKELDFKMLSNLTDLQECIRTqLNKTPELTKLVVDLSNCGPDDAFSSVPYIKGSTFLRYLEDLfGGPTVF 473
Cdd:cd09599  318 ERRILERLYGEEYRQFEAILGWKDLQESIKE-FGEDPPYTLLVPDLKGVDPDDAFSSVPYEKGFQFLYYLEQL-GGREVF 395
                        410       420       430       440
                 ....*....|....*....|....*....|....*....|....*..
gi 939619640 474 EPFLRDYLKKYAYKSIETKDFQSALYDYFIDtDKKDKLSAVDWDLWL 520
Cdd:cd09599  396 DPFLRAYFKKFAFQSIDTEDFKDFLLEYFAE-DKPEILDKIDWDAWL 441
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
72-528 5.14e-97

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 311.19  E-value: 5.14e-97
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  72 MGRLGVVDPssYsQPDLITTEHSALNWKIDFAATKIQGSVLHRFKVLTANLDKILLDVRDINVTNATLlaGGSELPinfF 151
Cdd:COG0308    1 MKRLTRLEA--Y-RPPGYDVTHYDLDLDLDPATTRLSGTATITFTATEAPLDSLVLDLKGLEVTSVTV--DGKPLD---F 72
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 152 ISDavddiGQKLTLELPSGTAKGSLN-VRIDYET--SSSASGLQWLNPTqtlGKEHPYMFSQCQAIHARSVIPCQDTPAV 228
Cdd:COG0308   73 TRD-----GERLTITLPKPLAPGETFtLEIEYSGkpSNGGEGLYRSGDP---PDGPPYLYTQCEPEGARRWFPCFDHPDD 144
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 229 KFTYDATVEHPSELTALMSA-LIDKKEPGKTL----FKQEVPIPAYLVAIAIGKLVSRPLGENSSV----WAEEAIVDAC 299
Cdd:COG0308  145 KATFTLTVTVPAGWVAVSNGnLVSETELGDGRttwhWADTQPIPTYLFALAAGDYAVVEDTFASGVplrvYVRPGLADKA 224
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 300 AEEFSETATMLKTATELCG-PYVWKQYDLLVMPpSFPFGGMENPCLTFVTPTLLAGD-------KSLADVVAHEIAHSWT 371
Cdd:COG0308  225 KEAFESTKRMLDFFEELFGvPYPFDKYDQVAVP-DFNFGAMENQGLVTFGEKVLADEtatdadyERRESVIAHELAHQWF 303
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 372 GNLVTNKNFEHFWLNEGFTVFVESKIVGRMQGAKELDFKMLSNLTDLQECIRTQLNKTPeltklVVDLSNCGPDDAFSSV 451
Cdd:COG0308  304 GNLVTCADWDDLWLNEGFATYMEQLFSEDLYGKDAADRIFVGALRSYAFAEDAGPNAHP-----IRPDDYPEIENFFDGI 378
                        410       420       430       440       450       460       470
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 939619640 452 PYIKGSTFLRYLEDLFgGPTVFEPFLRDYLKKYAYKSIETKDFQSALYDYfidTDKkdKLSAVdWDLWLKSEGMPPV 528
Cdd:COG0308  379 VYEKGALVLHMLRTLL-GDEAFRAGLRLYFARHAGGNATTEDFLAALEEA---SGR--DLSAF-FDQWLYQAGLPTL 448
M1 cd09595
Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 ...
160-500 3.79e-94

Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 hydrolase; The model represents the catalytic domains of M1 peptidase family members including aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). All peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile upon activation during catalysis. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. APN expression is dysregulated in many inflammatory diseases and is enhanced in numerous tumor cells, making it a lead target in the development of anti-cancer and anti-inflammatory drugs. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase in LTA4H is as yet unknown, while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals.


Pssm-ID: 341058 [Multi-domain]  Cd Length: 413  Bit Score: 297.43  E-value: 3.79e-94
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 160 GQKLTLELPSgTAKGSLNVRIDYETSSSASGLQWLNpTQTLGKEHPYMFSQCQAIHARSVIPCQDTPAVKFTYDATVEHP 239
Cdd:cd09595   62 GEKLTIPGPK-PPGQTFTVRISFEAKPSKNLLGWLW-EQTAGKEKPYLFTQFEATHARRIFPCIDHPAVKATFTVTITTP 139
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 240 S-ELTALMSALIDKKEPGKTL----FKQEVPIPAYLVAIAIGKLVSRPLGENS------SVWAEEAIVDACAEEFSETAT 308
Cdd:cd09595  140 KkDLLASNGALVGEETGANGRktyrFEDTPPIPTYLVAVVVGDLEFKYVTVKSqprvglSVYSEPLQVDQAQYAFDATRA 219
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 309 MLKTA-TELCGPYVWKQYDLlVMPPSFPFGGMENPCLTFVTPTLLA-------GDKSLADVVAHEIAHSWTGNLVTNKNF 380
Cdd:cd09595  220 ALAWFeDYFGGPYPLPKYDL-LAVPDFNSGAMENPGLITFRTTYLLrskvtdtGARSIENVIAHELAHQWFGNLVTMRWW 298
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 381 EHFWLNEGFTVFVESKIVGRMQGAKELDFKMLSNLTDLQEcIRTQLNKTPELTKLVVDLSncgPDDAFSSVPYIKGSTFL 460
Cdd:cd09595  299 NDLWLNEGFAVYYENRIMDATFGTSSRHLDQLSGSSDLNT-EQLLEDSSPTSTPVRSPAD---PDVAYDGVTYAKGALVL 374
                        330       340       350       360
                 ....*....|....*....|....*....|....*....|
gi 939619640 461 RYLEDLFgGPTVFEPFLRDYLKKYAYKSIETKDFQSALYD 500
Cdd:cd09595  375 RMLEELV-GEEAFDKGVQAYFNRHKFKNATTDDFIDALEE 413
M1_APN_like cd09603
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly ...
92-498 6.69e-64

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly bacterial and some archaeal M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341066 [Multi-domain]  Cd Length: 410  Bit Score: 217.45  E-value: 6.69e-64
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  92 EHSALNWKIDFAATKIQGSVLHRFKVlTANLDKILLDVRDINVTNATLlaggSELPINFFISDavddiGQKLTLELPSGT 171
Cdd:cd09603    4 LHYDLDLDYDPATKSLSGTATITFRA-TQDLDSLQLDLVGLTVSSVTV----DGVPAAFFTHD-----GDKLVITLPRPL 73
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 172 AKG-SLNVRIDYETSSSASGLQWLNPTQTLGKeHPYMFSQCQAIHARSVIPCQDTPAVKFTYDATVEHPSELTALmS--A 248
Cdd:cd09603   74 AAGeTFTVTVRYSGKPRPAGYPPGDGGGWEEG-DDGVWTAGQPEGASTWFPCNDHPDDKATYDITVTVPAGLTVV-SngR 151
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 249 LIDKKEP--GKTLF--KQEVPIPAYLVAIAIGKLVSRPLGENSSV----WAEEAIVDACAEEFSETATMLKTATELCGPY 320
Cdd:cd09603  152 LVSTTTNggGTTTWhwKMDYPIATYLVTLAVGRYAVVEDGSGGGIplryYVPPGDAAKAKASFARTPEMLDFFEELFGPY 231
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 321 VWKQYDLLVMPPSFpfGGMENPCLTFVTPTLLAGDKSLADVVAHEIAHSWTGNLVTNKNFEHFWLNEGFTVFVESKIVGR 400
Cdd:cd09603  232 PFEKYGQVVVPDLG--GGMEHQTATTYGNNFLNGDRGSERLIAHELAHQWFGDSVTCADWADIWLNEGFATYAEWLWSEH 309
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 401 MQGAKELDFKMLSNLTDLqecirtqLNKTPELTKLVvdlsncGPDDAFSSVPYIKGSTF---LRYLedlfGGPTVFEPFL 477
Cdd:cd09603  310 KGGADAYRAYLAGQRQDY-------LNADPGPGRPP------DPDDLFDRDVYQKGALVlhmLRNL----LGDEAFFAAL 372
                        410       420
                 ....*....|....*....|.
gi 939619640 478 RDYLKKYAYKSIETKDFQSAL 498
Cdd:cd09603  373 RAYLARYAHGNVTTEDFIAAA 393
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
96-498 1.76e-56

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 198.57  E-value: 1.76e-56
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  96 LNWKIDFAATKIQGSVLHRFKVLTANlDKILLDVRDINVTNATLLAGGSELPINffISDAVDDIGQKLTLELPSGTAKGS 175
Cdd:cd09601    5 LTLTPDLENFTFSGSVTITLEVLEPT-DTIVLHAKDLTITSASLTLKGGSGIIE--VTVVTDEETEFLTITLDETLPPGE 81
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 176 -LNVRIDY--ETSSSASGLQWLNPTQTLGKEHPYMFSQCQAIHARSVIPCQDTPAVKFTYDATVEHPSELTAL--MsALI 250
Cdd:cd09601   82 nYTLSIEFtgKLNDDLRGFYRSSYTDEDGETRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHPKGYTALsnM-PPV 160
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 251 DKKEPG----KTLFKQEVPIPAYLVAIAIGKLVSRPLGENS----SVWAEEAIVDACAEEFSETATMLKTATELCG-PYV 321
Cdd:cd09601  161 ESTELEdgwkTTTFETTPPMSTYLVAFVVGDFEYIESTTKSgvpvRVYARPGKIEQGDFALEVAPKILDFYEDYFGiPYP 240
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 322 WKQYDLLVMPpSFPFGGMENP-CLTFVTPTLLAGDKS--------LADVVAHEIAHSWTGNLVTNKNFEHFWLNEGFTVF 392
Cdd:cd09601  241 LPKLDLVAIP-DFAAGAMENWgLITYRETALLYDPKTssasdkqrVAEVIAHELAHQWFGNLVTMKWWDDLWLNEGFATY 319
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 393 VESKIVGRMQgaKELDFKMLSNLTDLQECIRT-QLNKTPELTKLVVDLSNCgpDDAFSSVPYIKGSTFLRYLEDLFgGPT 471
Cdd:cd09601  320 MEYLAVDKLF--PEWNMWDQFVVDELQSALELdSLASSHPIEVPVESPSEI--SEIFDAISYSKGASVLRMLENFL-GEE 394
                        410       420
                 ....*....|....*....|....*..
gi 939619640 472 VFEPFLRDYLKKYAYKSIETKDFQSAL 498
Cdd:cd09601  395 VFRKGLRKYLKKHAYGNATTDDLWEAL 421
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
319-519 7.28e-52

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 178.64  E-value: 7.28e-52
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  319 PYVWKQYDLLVMPpSFPFGGMENPCLTFVTPTLLAGD---------KSLADVVAHEIAHSWTGNLVTNKNFEHFWLNEGF 389
Cdd:pfam01433  20 PYPLPKYDLVALP-DFSAGAMENWGLITYRETLLLYDpgnsstsdkQRVASVIAHELAHQWFGNLVTMKWWDDLWLNEGF 98
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  390 TVFVESKIVGRMQGakelDFKMLSNLTDLQECIRTQLNKTPELTKLVVDLSNCG-PDDAFSSVPYIKGSTFLRYLEDLFg 468
Cdd:pfam01433  99 ATYMEYLGTDALFP----EWNIWEQFLLDEVQNAMARDALDSSHPITQNVNDPSeIDDIFDAIPYEKGASVLRMLETLL- 173
                         170       180       190       200       210
                  ....*....|....*....|....*....|....*....|....*....|.
gi 939619640  469 GPTVFEPFLRDYLKKYAYKSIETKDFQSALYDYfidTDKKDkLSAVdWDLW 519
Cdd:pfam01433 174 GEEVFQKGLRSYLKKFQYGNATTEDLWDALSEA---SGPLD-VDSF-MDTW 219
M1_APN cd09602
Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the ...
94-519 1.75e-41

Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the catalytic domain of bacterial and eukaryotic aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341065 [Multi-domain]  Cd Length: 440  Bit Score: 156.91  E-value: 1.75e-41
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  94 SALNWKIDF----AATKIQGSVLHRFKvLTANLDKILLDVRDINVTNATLlaGGSELPINFFisdavddigQKLTLELPS 169
Cdd:cd09602   14 SVVSYDLDLdlteGAETFRGTVTIRFT-LREPGASLFLDFRGGEVKSVTL--NGRPLDPSAF---------DGERITLPG 81
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 170 GTAKGSLNVRIDYET--SSSASGLQWLNPTQTlGKEhpYMFSQCQAIHARSVIPCQDTPAVKFTYDATVEHPSELTALMS 247
Cdd:cd09602   82 LLKAGENTVVVEFTApySSDGEGLHRFVDPAD-GET--YLYTLFEPDDARRVFPCFDQPDLKATFTLTVTAPADWTVISN 158
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 248 ALIDKKEPGKTL----FKQEVPIPAYLVAIAIGKLVS-------RPLGenssVWAEEAIV--DACAEE-FSETATMLKTA 313
Cdd:cd09602  159 GPETSTEEAGGRkrwrFAETPPLSTYLFAFVAGPYHRvedehdgIPLG----LYCRESLAeyERDADEiFEVTKQGLDFY 234
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 314 TELCG-PYVWKQYDLlVMPPSFPFGGMENP-CLTF---------VTPTLLAGdksLADVVAHEIAHSWTGNLVTNKNFEH 382
Cdd:cd09602  235 EDYFGiPYPFGKYDQ-VFVPEFNFGAMENPgAVTFresylfreePTRAQRLR---RANTILHEMAHMWFGDLVTMKWWDD 310
                        330       340       350       360       370       380       390       400
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 383 FWLNEGFTVFVESKIVGRMQGAKELDFKMLSN------LTDlqecirtQLNKT-PeltkLVVDLSNcgPDDAFS---SVP 452
Cdd:cd09602  311 LWLNESFADFMAAKALAEATPFTDAWLTFLLRrkpwayRAD-------QLPTThP----IAQDVPD--LEAAGSnfdGIT 377
                        410       420       430       440       450       460       470
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 453 YIKGSTFLRYLEDLFGgptvFEPF---LRDYLKKYAYKSIETKDFQSALydyfidtdkkDKLSAVDWDLW 519
Cdd:cd09602  378 YAKGASVLKQLVALVG----EEAFragLREYFKKHAYGNATLDDLIAAL----------DEASGRDLSAW 433
Leuk-A4-hydro_C pfam09127
Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of ...
568-681 1.94e-33

Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of two layers of parallel alpha-helices, five in the inner layer and four in the outer, arranged in an antiparallel manner, with perpendicular loops containing short helical segments on top. They are required for the formation of a deep cleft harbouring the catalytic Zn2+ site in Leukotriene A4 hydrolase.


Pssm-ID: 462686  Cd Length: 112  Bit Score: 123.75  E-value: 1.94e-33
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  568 HQLIDFLGKLIESKDivdLNEGKINLLESTYNLKSSKNAEVRFRLNRLIIRARLIKRLDEILEFANSNFRMKFCRPIYRD 647
Cdd:pfam09127   4 NQKVVFLERLLEFSP---LSPEQLKALDEVYKLSESKNAEIRFRWLRLALKAKYEPAYPEVAEFLGEVGRMKFVRPLYRA 80
                          90       100       110
                  ....*....|....*....|....*....|....
gi 939619640  648 LAGWPeaKPAAIRNFVNVKDQMMAVCSHTIEKDL 681
Cdd:pfam09127  81 LNKVD--RDLAVETFEKNKDFYHPICRAMVEKDL 112
M1_APN_like cd09604
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains ...
231-498 4.35e-26

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains bacterial M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341067 [Multi-domain]  Cd Length: 440  Bit Score: 111.60  E-value: 4.35e-26
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 231 TYDATVEHPSELT-----ALMSALIDKKEPGKTLFKQE-------VPIPAYLVAIAIG---KLVSRPLGENSSVWAE--E 293
Cdd:cd09604  162 DYDVTITVPKNYVvaatgELQNPEEVLDGTKTWHFKAEnvrdfawAASPDFVVDAATVdgvTVNVYYLPENAEAAERalE 241
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 294 AIVDAcaeefsetatmLKTATELCGPYVWKQYDllVMPPSFPFGGMENPCLTFVTPTLLAGDKSLADVVAHEIAHSWTGN 373
Cdd:cd09604  242 YAKDA-----------LEFFSEKFGPYPYPELD--VVQGPFGGGGMEYPGLVFIGSRLYDPKRSLEGVVVHEIAHQWFYG 308
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 374 LVTNKNFEHFWLNEGFTVFVESKIVGRMQGAKELDFKMLSNLTDLQECIRTQLNKTPeltklVVDLSNcgpDDAFSSVPY 453
Cdd:cd09604  309 IVGNDERREPWLDEGLATYAESLYLEEKYGKEAADELLGRRYYRAYARGPGGPINLP-----LDTFPD---GSYYSNAVY 380
                        250       260       270       280
                 ....*....|....*....|....*....|....*....|....*
gi 939619640 454 IKGSTFLRYLEDLFgGPTVFEPFLRDYLKKYAYKSIETKDFQSAL 498
Cdd:cd09604  381 SKGALFLEELREEL-GDEAFDKALREYYRRYKFKHPTPEDFFRTA 424
Peptidase_M1_N pfam17900
Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from ...
91-270 1.82e-24

Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from the M1 family.


Pssm-ID: 465557 [Multi-domain]  Cd Length: 186  Bit Score: 100.88  E-value: 1.82e-24
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640   91 TEHSALNWKIDFAATKIQGSVLHRFKVlTANLDKILLDVRDINVTNATLLAGGS--ELPINFFIsdaVDDIGQKLTLELP 168
Cdd:pfam17900   2 PEHYDLDLKIDLKNFTFSGSVTITLQL-NNATNVIVLHASDLTIRSISLSDEVTsdGVPADFTE---DQKDGEKLTIVLP 77
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  169 SGT-AKGSLNVRIDYET--SSSASGLQWLNPTQTlGKEHPYMFSQCQAIHARSVIPCQDTPAVKFTYDATVEHPSELTAL 245
Cdd:pfam17900  78 ETLnQTGPYTLEIEYSGelNDSMTGFYRSTYTDN-GEKKVLVTTQFEPTDARSAFPCFDEPSVKATFTISIIHPKDYTAL 156
                         170       180       190
                  ....*....|....*....|....*....|
gi 939619640  246 --MSAL-IDKKEPG--KTLFKQEVPIPAYL 270
Cdd:pfam17900 157 snMPVIaSEPLENGwvITTFEQTPKMSTYL 186
GluZincin cd09594
Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, ...
303-397 2.07e-20

Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, M2, M3, M4, M13, M32 and M36 (fungalysins); The Gluzincin family (thermolysin-like peptidases or TLPs) includes several zinc-dependent metallopeptidases such as M1, M2, M3, M4, M13, M32, M36 peptidases (MEROPS classification), which contain the HEXXH motif as part of their active site. Peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. The M1 family includes aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity such that the two activities occupy different, but overlapping sites. The M3_like peptidases include the M2_ACE, M3 or neurolysin-like family (subfamilies M3B_PepF and M3A) and M32_Taq peptidases. The M2 peptidase angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of decapeptide angiotensin I to the potent vasopressor octapeptide angiotensin II. ACE is a key component of the renin-angiotensin system that regulates blood pressure, thus ACE inhibitors are important for the treatment of hypertension. M3A includes thimet oligopeptidase (TOP; endopeptidase 3.4.24.15), neurolysin (3.4.24.16), and the mitochondrial intermediate peptidase; and M3B includes oligopeptidase F. The M32 family includes eukaryotic enzymes from protozoa Trypanosoma cruzi, a causative agent of Chagas' disease, and from Leishmania major, a parasite that causes leishmaniasis, making these enzymes attractive targets for drug development. The M4 family includes secreted protease thermolysin (EC 3.4.24.27), pseudolysin, aureolysin, and neutral protease as well as bacillolysin (EC 3.4.24.28) that degrade extracellular proteins and peptides for bacterial nutrition, especially prior to sporulation. Thermolysin is widely used as a nonspecific protease to obtain fragments for peptide sequencing as well as in production of the artificial sweetener aspartame. The M13 family includes neprilysin (EC 3.4.24.11) and endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), which fulfill a broad range of physiological roles due to the greater variation in the S2' subsite allowing substrate specificity and are prime therapeutic targets for selective inhibition. The peptidase M36 fungalysin family includes endopeptidases from pathogenic fungi. Fungalysin hydrolyzes extracellular matrix proteins such as elastin and keratin. Aspergillus fumigatus causes the pulmonary disease aspergillosis by invading the lungs of immuno-compromised animals and secreting fungalysin that possibly breaks down proteinaceous structural barriers.


Pssm-ID: 341057 [Multi-domain]  Cd Length: 105  Bit Score: 86.77  E-value: 2.07e-20
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 303 FSETATMLKTATELCG-----PYVWKQYDLLVMPP---SFPFGGMENP-CLTFVTPTLLAGDKSLADVVAHEIAHSWTGN 373
Cdd:cd09594    1 TSYAHETYKYYEELLGrtsfrYPVSPIYSLLVYPAyveVNAYNAMWIPsTNIFYGAGILDTLSGTIDVLAHELTHAFTGQ 80
                         90       100
                 ....*....|....*....|....*
gi 939619640 374 LVTNK-NFEHFWLNEGFTVFVESKI 397
Cdd:cd09594   81 FSNLMySWSSGWLNEGISDYFGGLV 105
M1_APN cd09600
Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the ...
83-392 2.34e-11

Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. It includes bacterial-type alanyl aminopeptidases as well as PfA-M1 aminopeptidase (Plasmodium falciparum-type). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341063 [Multi-domain]  Cd Length: 434  Bit Score: 66.38  E-value: 2.34e-11
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640  83 YSQPD-LIttEHSALNWKIDFAATKIQgSVLH-RFKVLTANLDKILLDVRDINVTNATLlaGGSELPINFFISDavddiG 160
Cdd:cd09600    2 YKPPDfLI--DHVDLDFDLDDDETIVT-SRLRvRRNPDSGEGAPLVLDGEDLELLSVKI--DGKPLSPSDYTLD-----E 71
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 161 QKLTLELPSGTAKGSLNVRIDYETSSSASGLQWLNPTqtlgkehpyMFSQCQAIHARSVIPCQDTPAVKFTYDATVEHP- 239
Cdd:cd09600   72 EGLTIKNVPDRFVLEIEVRINPAANTSLEGLYKSGGI---------LCTQCEAEGFRRITYFPDRPDVMSKFTVTIEADk 142
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 240 SELTALMS--ALIDKKE--PGK--TLFKQEVPIPAYLVAIAIGKLVSR------PLGENSS--VWAEEAIVDAC--AEEF 303
Cdd:cd09600  143 EKYPVLLSngNLIEEGElpNGRhfAVWEDPFPKPSYLFALVAGDLGSVedtfttKSGRKVKlrIYVEPGNEDKChhAMES 222
                        250       260       270       280       290       300       310       320
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 304 setatmLKTATElcgpyvW------KQYDL----LVMPPSFPFGGMENPCLT-FVTPTLLAGDKSLAD--------VVAH 364
Cdd:cd09600  223 ------LKKAMK------WdeerfgLEYDLdlfnIVAVDDFNMGAMENKGLNiFNSKYVLADPETATDadyeriesVIAH 290
                        330       340
                 ....*....|....*....|....*...
gi 939619640 365 EIAHSWTGNLVTNKNFEHFWLNEGFTVF 392
Cdd:cd09600  291 EYFHNWTGNRVTCRDWFQLSLKEGLTVF 318
Ribosomal_L13 pfam00572
Ribosomal protein L13;
15-50 6.95e-08

Ribosomal protein L13;


Pssm-ID: 459856  Cd Length: 119  Bit Score: 51.42  E-value: 6.95e-08
                          10        20        30
                  ....*....|....*....|....*....|....*.
gi 939619640   15 RTWHIYDCTWQNPFESAKLVKTHLLGLQKPIYHPMI 50
Cdd:pfam00572   1 RKWHVVDAKGQILGRLASKIAKLLRGKHKPIYHPHV 36
M1_like_TAF2 cd09839
TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) ...
100-295 1.53e-06

TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) associated factor 2 (TAF2, TBP-associated factor TAFII150, transcription initiation factor TFIID subunit 2, RNA polymerase II TBP-associated factor subunit B), and has homology to the M1 gluzincin family. TAF2 is part of the TFIID multidomain subunit complex essential for transcription of most protein-encoded genes by RNA polymerase II. TAF2 is known to interact with the initiator element (Inr) found at the transcription start site of many genes, thus possibly playing a key role in promoter binding as well as start-site selection. Image analysis has shown TAF2 to form a complex with TAF1 and TBP, inferring its role in promoter recognition. Peptidases in the M1 family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. TAF2, however, lacks these active site residues.


Pssm-ID: 341074 [Multi-domain]  Cd Length: 531  Bit Score: 51.46  E-value: 1.53e-06
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 100 IDFAATKIQGSVLHRFKVLTANLDKILLDVRDINVTNATL---------------------------------------- 139
Cdd:cd09839   10 VDFANRSIIGYTEITIVPTSPDLRTIRLNCRQCKIKSVTVngveaeftyndplqnldlsdntdvnahhelkrklaaalae 89
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 140 -LAGGSELPINF---FISDAVDDIGQKLTLELPSGTAKGS----LNVRIDYETSSSASGLQWLNPTQTLGKEHPYMFSQC 211
Cdd:cd09839   90 pDEGNEELVISLppsVKIELQDPNSASTQATTSSPDTSEDeftpLTIRIEYSLKNPRDGLHFVGPDEGGDKRYPHVYTTN 169
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 939619640 212 QAIH--ARSVIPCQDTPA------VKFTYDATV-----------------------EHPSELTALMSA-LIDKKEPG--- 256
Cdd:cd09839  170 SPLPgsARCWFPCVDSLWerctweLEITVPRTLgdagrpplagskededdddlteeDKELEMVVVCSGdLVEQVVHPedp 249
                        250       260       270       280
                 ....*....|....*....|....*....|....*....|..
gi 939619640 257 --KT-LFKQEVPIPAYLVAIAIGKLVSRPLGENSSVWAEEAI 295
Cdd:cd09839  250 skKTfSFSLSNPTSAQHIGFAVGPFEIVPLPEFRESEEDDKL 291
Ribosomal_L13 cd00392
Ribosomal protein L13. Protein L13, a large ribosomal subunit protein, is one of five ...
17-52 1.51e-05

Ribosomal protein L13. Protein L13, a large ribosomal subunit protein, is one of five proteins required for an early folding intermediate of 23S rRNA in the assembly of the large subunit. L13 is situated on the bottom of the large subunit, near the polypeptide exit site. It interacts with proteins L3 and L6, and forms an extensive network of interactions with 23S rRNA. L13 has been identified as a homolog of the human breast basic conserved protein 1 (BBC1), a protein identified through its increased expression in breast cancer. L13 expression is also upregulated in a variety of human gastrointestinal cancers, suggesting it may play a role in the etiology of a variety of human malignancies.


Pssm-ID: 238230  Cd Length: 114  Bit Score: 44.42  E-value: 1.51e-05
                         10        20        30
                 ....*....|....*....|....*....|....*.
gi 939619640  17 WHIYDCTWQNPFESAKLVKTHLLGLQKPIYHPMIST 52
Cdd:cd00392    1 WHVIDAKGQVLGRLASKVAKLLLGKHKPTYTPHVDC 36
pepN PRK14015
aminopeptidase N; Provisional
361-392 9.08e-04

aminopeptidase N; Provisional


Pssm-ID: 237585 [Multi-domain]  Cd Length: 875  Bit Score: 42.43  E-value: 9.08e-04
                         10        20        30
                 ....*....|....*....|....*....|....*.
gi 939619640 361 VVAHEIAHSWTGNLVTNKNfehfW----LNEGFTVF 392
Cdd:PRK14015 299 VIAHEYFHNWTGNRVTCRD----WfqlsLKEGLTVF 330
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH